{"id":"W3018886418","doi":"10.1016/s1474-4422(20)30078-8","title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":490,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"National Eye Institute; Genentech; Multiple Sclerosis Society of Canada; Japan Blood Products Organization; National Institutes of Health; Guthy-Jackson Charitable Foundation; Patient-Centered Outcomes Research Institute; Bayer Canada; Bayer; Biogen; Teva Pharmaceutical Industries; Otsuka Pharmaceutical; Novartis; National Multiple Sclerosis Society; MedImmune; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Roche","keywords":"Medicine; Placebo; Clinical endpoint; Population; Neuromyelitis optica; Internal medicine; Clinical trial; Intention-to-treat analysis; Pediatrics; Antibody; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005759035,0.0002608009,0.001681974,0.0001039361,0.00008255842,0.00001692345,0.0002550833,0.00009734854,0.0001219723],"category_scores_gemma":[0.001310655,0.0001652496,0.0001862634,0.000252314,0.0003566691,0.00004151678,0.0001272475,0.0005980394,0.000008721595],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001288106,"about_ca_system_score_gemma":0.00006317964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001255343,"about_ca_topic_score_gemma":0.0001088952,"domain_scores_codex":[0.9972987,0.00068996,0.0006895537,0.0004590281,0.0002868421,0.0005759863],"domain_scores_gemma":[0.9968246,0.002365702,0.0001869355,0.0004160696,0.00003743425,0.0001693204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9897336,0.0004615115,0.0009343643,0.00005539929,0.0002376413,0.00006792016,0.001151634,0.0001622232,0.002089753,0.0001062258,0.0001193635,0.00488032],"study_design_scores_gemma":[0.9782652,0.003869453,0.006472593,0.0000139957,0.0001075276,0.0000157104,0.00003494387,0.008023776,0.0001761933,0.00001851225,0.002888914,0.0001132332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9000945,0.000645647,0.00006819394,0.09217007,0.0001086318,0.006374312,0.0000218128,0.00005060458,0.0004661967],"genre_scores_gemma":[0.9908444,0.005944283,0.00005342416,0.002260611,0.0006194115,0.0002135241,0.000009175896,0.00003275477,0.0000223713],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09074991,"threshold_uncertainty_score":0.6738683,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06748685005283493,"score_gpt":0.3488388857934585,"score_spread":0.2813520357406236,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}